logo
  

Jacobs Engineering Group Renews Project Representative Role For Crossrail

Jacobs Engineering Group Inc. (JEC) announced it was reappointed as Project Representative for the $22 billion or 14.8 billion pounds Crossrail program by the UK's Department for Transport or DfT and Transport for London or TfL.

Company officials did not disclose the contract value, but noted that the contract is renewed for a term of up to five years.

The Crossrail program is expected to run over 100km from Reading and Heathrow in the west, through new tunnels under central London to the east, with 40 stations including 10 new stations. The first Crossrail services through central London are expected to start in late 2018. It is expected to increase London's rail capacity by 10 percent and improve connectivity for an estimated 200 million annual passengers.

Separately, Jacobs Engineering Group announced today that, after a competitive process, its Consultancy business was awarded a contract by the Department of Energy and Climate Change (DECC), a department of the United Kingdom Government, to provide technical advisory services to DECC's Office of Carbon Capture & Storage (OCCS).

DECC has developed one of the most comprehensive programs in the world to support creation of a new carbon capture and storage (CCS) industry to help mitigate climate change.

Company officials did not disclose the contract value, but noted that the two-year contract is being delivered from its London operations.

The UK CCS Commercialization Program has $1.55 billion or 1 billion pounds capital funding available to support the practical experience in the design, construction and operation of commercial-scale CCS.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT